Tandem Diabetes Care, Inc. Geena George Director, Regulatory Affairs 12400 High Bluff Drive San Diego, California 92130

Re: K243823 Trade/Device Name: Control- $\mathrm { { I Q + } }$ technology Regulation Number: 21 CFR 862.1356 Regulation Name: Interoperable Automated Glycemic Controller Regulatory Class: Class II Product Code: QJI Dated: December 12, 2024 Received: December 12, 2024

Dear Geena George:

We have reviewed your section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical  
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn   
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# Joshua Balsam -S

Joshua M. Balsam, Ph.D.   
Branch Chief   
Division of Chemistry   
and Toxicology Devices   
OHT7: Office of In Vitro Diagnostics   
Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

# Indications for Use

<table><tr><td>Submission Number (if known)</td></tr><tr><td>K243823</td></tr><tr><td>Device Name</td></tr><tr><td>Control-IQ+ technology</td></tr><tr><td>Indications for Use (Describe) Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors</td></tr><tr><td>(iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold.</td></tr><tr><td></td></tr><tr><td>Control-IQ+ technology is intended for the management of Type 1 diabetes mellitus in persons 2</td></tr><tr><td>years of age and greater and of Type 2 diabetes mellitus in persons 18 years of age and greater. Control-IQ+ technology is intended for single patient use and requires a prescription.</td></tr></table>

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) SUMMARY

<table><tr><td rowspan=1 colspan=1>Company</td><td rowspan=1 colspan=1>Tandem Diabetes Care, Inc12400 High Bluff DriveSan Diego, CA 92130</td></tr><tr><td rowspan=1 colspan=1>Prepared</td><td rowspan=1 colspan=1>12 Dec 2024</td></tr><tr><td rowspan=1 colspan=1>Contact</td><td rowspan=1 colspan=1>Geena GeorgeDirector of Regulatory Affairsggeorge@tandemdiabetes.com</td></tr><tr><td rowspan=1 colspan=1>Trade Name</td><td rowspan=1 colspan=1>Control-IQ+ technology</td></tr><tr><td rowspan=1 colspan=1>Common Name</td><td rowspan=1 colspan=1>Interoperable Automated Glycemic Controller</td></tr><tr><td rowspan=1 colspan=1>Classification Product Code</td><td rowspan=1 colspan=1>QJI</td></tr><tr><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>Interoperable Automated Glycemic Controller</td></tr><tr><td rowspan=1 colspan=1>Regulation Number</td><td rowspan=1 colspan=1>21 CFR 862.1356</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>Class II</td></tr><tr><td rowspan=1 colspan=1>Predicate Device</td><td rowspan=1 colspan=1>K232382, Control-IQ Technology</td></tr></table>

# I. Device Under Review

Control- $\mathrm { { I Q + } }$ technology (Control- $\cdot \mathrm { I Q + }$ , the device) is a software-only device intended for the management of type 1 and type 2 diabetes mellitus. The device controls insulin delivery from a compatible alternate controller enabled insulin pump (ACE pump) based on inputs provided by a compatible integrated continuous glucose monitor (iCGM) and inputs provided by the user (e.g., carbohydrate intake, exercise, and sleep schedule). Control- $\mathrm { { I Q + } }$ technology is meant to be installed on a compatible ACE pump.

Control- $\cdot \mathrm { I Q + }$ technology has three different modes: Normal, Sleep, and Exercise. The glucose targets are not individually customizable in these modes but can change based on the mode selected. During normal mode, Control- $\mathrm { I Q + }$ technology aims to control glucose within a target range of $1 1 2 . 5 - 1 6 0 \mathrm { m g / d L }$ . During sleep mode, this range is changed to $1 1 2 . 5 { - } 1 2 0 \ \mathrm { m g / d L }$ , and it is changed to $1 4 0 { - } 1 6 0 \ \mathrm { m g / d L }$ during exercise mode.

Control- $\cdot \mathrm { I Q + }$ technology includes an integrated feature whereby iCGM values are automatically populated into the glucose field of the integrated bolus calculator when ControlIQ $^ +$ technology is active (i.e., the device is operating in closed-loop mode). This feature is disabled when Control-IQ is turned off.

Control-IQ $^ +$ technology requires users to input their weight and their total daily insulin requirement, which should be established with the help of a health care provider before using the device.

# II. Intended Use/ Indications for Use

Control- $\cdot \mathrm { I Q + }$ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold.

Control- $\cdot \mathrm { I Q + }$ technology is intended for the management of Type 1 diabetes mellitus in persons 2 years of age and greater and of Type 2 diabetes mellitus in persons 18 years of age and greater.

Control- $\cdot \mathrm { I Q + }$ technology is intended for single patient use and requires a prescription.

III. Technological Characteristics Compared to Predicate Device K232382   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate DeviceK232382</td><td colspan="1" rowspan="1">Subject Device</td></tr><tr><td colspan="1" rowspan="1">Indications forUse/ IntendedUse</td><td colspan="1" rowspan="1">Control-IQ technology is intendedfor use with compatible integratedcontinuous glucose monitors(iCGM) and alternate controllerenabled (ACE) pumps toautomatically increase, decrease,and suspend delivery of basalinsulin based on iCGM readingsand predicted glucose values. Itcan also deliver correction boluseswhen the glucose value ispredicted to exceed a predefinedthreshold.Control-IQ technology is intendedfor the management of Type 1diabetes mellitus in persons2years of age and greater.Control-IQ technology is intendedfor single patient use and requiresa prescription.</td><td colspan="1" rowspan="1">Control-IQ+ technology isintended for use with compatibleintegrated continuous glucosemonitors (iCGM) and alternatecontroller enabled (ACE) pumpsto automatically increase,decrease, and suspend delivery ofbasal insulin based on iCGMreadings and predicted glucosevalues. It can also delivercorrection boluses when theglucose value is predicted toexceed a predefined threshold.Control-IQ+ technology isintended for the management ofType 1 diabetes mellitus inpersons 2 years of age and greaterand of Type 2 diabetes mellitusin persons 18 years of age andgreater.Control-IQ+ technology isintended for single patient use andrequires a prescription.</td></tr><tr><td colspan="1" rowspan="1">Pump Type</td><td colspan="1" rowspan="1">Alternate controller enabledinsulin pump</td><td colspan="1" rowspan="1">SAME</td></tr><tr><td colspan="1" rowspan="1">SpecificDrug/BiologicalUse</td><td colspan="1" rowspan="1">U-100 Insulin</td><td colspan="1" rowspan="1">SAME</td></tr><tr><td colspan="1" rowspan="1">Profile Delivery</td><td colspan="1" rowspan="1">When the predicted CGM value iswithin the target range, the pumpwill deliver insulin at the ratedetermined by the active PersonalProfile settings.The user's profile basal rate maybe set as high as 15 units/hr whenControl-IQ is off and whenControl-IQ is enabled same basalrate is applied.</td><td colspan="1" rowspan="1">SAME</td></tr><tr><td colspan="1" rowspan="1">Basal RateRange</td><td colspan="1" rowspan="1">The Personal Profile correctionfactor is used to determine thepredicted basal rate limits of 10 to600 mg/dL per unit insulin.</td><td colspan="1" rowspan="1">SAME</td></tr><tr><td colspan="1" rowspan="1">BasalAttenuation</td><td colspan="1" rowspan="1">When Control-IQ technologypredicts that the sensor glucosevalue will be at or below thetarget range 30 minutes in thefuture, the rate of insulindelivered will begin to decrease toattempt to keep glucose within thetarget range.</td><td colspan="1" rowspan="1">SAME</td></tr><tr><td colspan="1" rowspan="1">AutomaticCorrectionBolus</td><td colspan="1" rowspan="1">The upper limit for the automaticcorrection bolus is 600 mg/dL perunit insulin.</td><td colspan="1" rowspan="1">SAME</td></tr><tr><td colspan="1" rowspan="1">Body WeightSetting Range</td><td colspan="1" rowspan="1">20 lbs (9 kg) âˆ’ 440 lbs (200 kg)</td><td colspan="1" rowspan="1">SAME</td></tr><tr><td colspan="1" rowspan="1">Total DailyInsulin SettingRange</td><td colspan="1" rowspan="1">User setting of 5 units/day - 200units/day</td><td colspan="1" rowspan="1">SAME</td></tr><tr><td colspan="1" rowspan="1">Extended Bolus</td><td colspan="1" rowspan="1">Up to 8-hour duration whileControl-IQ is enabled or disabledand extended boluses areuninterrupted when enablingControl-IQ.</td><td colspan="1" rowspan="1">SAME</td></tr><tr><td colspan="1" rowspan="1">TemporaryBasal Rate</td><td colspan="1" rowspan="1">Temp Rates can be enabledwithout turning Control-IQTechnology off</td><td colspan="1" rowspan="1">SAME</td></tr></table>

# Overview of Non-Clinical and Clinical Performance Tests

Appropriate testing was performed to confirm the Subject Device met specified requirements and performed as intended. See summaries below.

# Usability/Human Factors:

A Summative Human Factors validation was performed and followed FDA recognized standard IEC 62366-1 as well as the FDA guidance document Applying Human Factors and Usability Engineering to Medical Devices (February 3, 2016). The validation study evaluated a total of 30 individuals with Type 2 diabetes. The purpose of the validation was to ensure individuals can safely and effectively perform critical tasks associated with the use of Control- $\cdot \mathrm { I Q + }$ technology.

# Software Verification and Validation:

No new software testing was performed to support this 510(k) Notification.

# Special Controls:

Evaluation and adherence to the Special Controls of the Predicate Device (K232382) demonstrates continued assurance of the safety and effectiveness of the Subject Device.

# Clinical Testing:

A pivotal clinical study was conducted to evaluate the safety and effectiveness of Control- $\cdot \mathrm { I Q + }$ technology in individuals with Type 2 diabetes ages 18 years and older. This randomized controlled trial enrolled 319 subjects and the subjects were randomly assigned to Control- $\cdot \mathrm { I Q + }$ or CGM with continued insulin injections in a 2:1 ratio. The primary outcome of this study was change in HbA1C between arms at 13 weeks.

# Conclusion:

The changes that have been made to the Control- $\cdot \mathrm { I Q + }$ technology indications for use result in a product that is substantially equivalent to the predicate Control-IQ technology device. The design of the Control- $\cdot \mathrm { I Q + }$ algorithm is unchanged. The intended use and indications for use have been previously cleared on the Tandem device except for the addition of the Type 2 users ages 18 years or older. The addition of a new user population is supported by clinical trial data that demonstrates that Control- $\cdot \mathrm { I Q + }$ technology is safe and effective in patients with Type 2 diabetes. Furthermore, the human factors validation with the new user population supports the safety of Control- $\cdot \mathrm { I Q + }$ technology. Thus, the modified Control- $\cdot \mathrm { I Q + }$ technology does not raise any different questions of safety and effectiveness and is considered substantially equivalent to the predicate, Control-IQ technology (K232382).